Peptides DB
Research-centric peptide and protocol reference hub
Study 33 of 33Erythropoietin (EPO) literatureAnnals of medicine · Meta-analysis2026

Prevalence and risk of cardiovascular events among people living with HIV: a meta-analysis.

People living with HIV have a 6% prevalence of cardiovascular events, influenced by various risk factors including age and smoking.

Read at Annals of medicineAdd to compare

Where it sits

this study against the rest of the erythropoietin (epo) corpus
5
Preclinical
21
Observational
1
Open-label
2
Randomised
4
Reviews · this one

Summary and findings

This meta-analysis assessed the prevalence and determinants of cardiovascular events among people living with HIV (PLWH). A total of 4,175,459 PLWH were included, with 166,225 cardiovascular events reported. The pooled prevalence of cardiovascular events was 6% (95% CI: 0.05-0.07).

How much of this paper we could read: full text read (0.90). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Pooled prevalence of cardiovascular events was 6% (95% CI: 0.05-0.07).2026

Abstract

The authors’ words, as Annals of medicine supplied them

<h4>Background</h4>People living with HIV (PLWH) have increased cardiovascular risk, but the contribution of HIV-related factors to all-cause cardiovascular events remains unclear. We assessed the prevalence and determinants of cardiovascular events in PLWH, including subtype-specific risk profiles.<h4>Methods</h4>PubMed, EMBASE, Cochrane Library, Web of Science and Scopus were searched from January 1, 2004 to October 31, 2024. Observational studies reporting cardiovascular event prevalence or adjusted risk estimates in PLWH were included. Two reviewers independently selected studies and extracted data. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using fixed- or random-effects models, and heterogeneity was assessed using Cochran's <i>Q</i> and <i>I<sup>2</sup></i> statistics.<h4>Results</h4>Forty-three studies including 4,175,459 PLWH and 166,225 cardiovascular events were analyzed. The pooled prevalence of cardiovascular events was 6% (95% CI: 0.05-0.07). Higher risk was associated with older age, smoking, antiretroviral therapy, male sex, CD4+ T-cell count <200 cells/mm3, detectable HIV viral load, dyslipidemia, hypertension, diabetes, syphilis coinfection, prior cardiovascular disease and elevated red cell distribution width. Higher CD4+ counts (per 100 cells/mm3) and Hispanic ethnicity were associated with lower risk. Subgroup analyses showed that smoking, antiretroviral therapy and dyslipidemia were linked to myocardial infarction; prior cardiovascular disease and CD4+ T-cell count <200 cells/mm3 to arrhythmia; and male sex, dyslipidemia, hypertension and syphilis coinfection to stroke.<h4>Conclusion</h4>PLWH have a substantial cardiovascular event burden driven by both traditional and HIV-related risk factors. Early cardiovascular risk assessment, viral suppression and immunological recovery should be prioritized.

Elsewhere in the Erythropoietin (EPO) corpus

BReal-world effectiveness of central dialysis fluid delivery system (CDDS) in maintenance hemodialysis: a retrospective multicenter study.Renal failure · 2026 · β = 3.50 g/L hemoglobin compared to SPDDS, p < 0.05HumanBImpaired fasting glucose is comparable to diabetes mellitus in predicting mortality and cardiovascular events in patients undergoing peritoneal dialysis: the role of β-cell function and insulin resistance.Renal failure · 2026 · n=216 · IFG independently predicted all-cause mortality (HR, 2.48; 95% CI, 1.16-5.32; p=0.02).HumanBThe relationship between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and tubular atrophy/interstitial fibrosis in patients with IgA nephropathy.Renal failure · 2026 · n=400 · NHHR was positively correlated with T lesions (r = 0.229, p < 0.001).HumanBAssociation Between Perioperative Daprodustat Use and Early Posttransplant Graft Function in Living Donor Kidney Transplantation: A Propensity Score-Matched Retrospective Study.Current therapeutic research, clinical and experimental · 2026 · n=64 · Week 1 estimated glomerular filtration rate: 53.3 ± 16.1 vs control 41.9 ± 17.9 mL/min/1.73 m²; P = 0.001HumanCAnalytical validation of an ultrasensitive multiplexed immunoassay for blood-based biomarkers GFAP, NF-L and taubiorxiv-preprint · 2026 · Intra-plate %CV averaged less than 10%.In vitroBPlasma erythropoietin responses across repeated exposure to normobaric hypoxia in healthy older adultsbiorxiv-preprint · 2026 · Plasma EPO increased by an estimated mean of 6.33 mIU/mL from baseline to 3 h post-exposure.Human